Primary sclerosing cholangitis
Drug research and approvals for primary sclerosing cholangitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 32 studies of primary sclerosing cholangitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, and FDA has 0 approved and 18 open orphan designations naming it.
- Recruiting worldwide: 32
- Trials authorized in Canada: 14
- FDA orphan approvals: 0
- EU medicines: 0
- Biodegradable Stents in Primary Sclerosing CholangitisNCT07607353 · Not applicable · King's College Hospital NHS Trust · starts Mar 1, 2026
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisNCT07387549 · Phase 3 · Ipsen · starts May 14, 2026
- Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing CholangitisNCT07341282 · Phase 2 · McMaster University · starts Jun 17, 2026
- A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)NCT07229911 · Phase 1 · Takeda · starts Jan 7, 2026
- Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationNCT06905054 · Phase 2 · Mayo Clinic · starts Apr 15, 2025
- Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing CholangitisNCT06865924 · Not applicable · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Dec 1, 2024
- A Simple Breath Test to Detect Liver Cancer and Monitor Liver ConditionsNCT06864195 · Not reported · Imperial College London · starts Feb 13, 2025
- Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)NCT06767605 · Not reported · Asociación Española para el Estudio del Hígado · starts Jan 1, 2016
- LEOPARD Prospective Validation Cohort 1NCT06723275 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jul 7, 2026
| Nov 5, 2025 | A double-blind randomized placebo-controlled investigation of vancomycin efficacy in patients with ulcerative colitis and primary sclerosing cholangitis…Vancomycin | McMaster University | Pending |
| Dec 2, 2024 | A phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of aldafermin in subjects with…Aldafermin (NGM282) | Ngm Biopharmaceuticals | Pending |
| Dec 8, 2022 | A phase II, multicenter, double-blind, randomised, placebo-controlled study and open-label long term extension to evaluate the safety and efficacy of…Elafibranor (IPN60190) | Ipsen | Ongoing |
| Aug 3, 2022 | Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547 | Escient Pharmceuticals Inc | Closed |
| Aug 19, 2021 | A randomized double-blind placebocontrolled study to evaluate the efficacy and safety of volixibat in the treatment of cholestatic pruritus in patients with…Volixibat (SHP626, LUM002) | Mirum Pharmaceuticals | Ongoing |
| Jun 18, 2020 | A randomized, double-blind, dose-ranging, placebo-controlled, phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in…PLN-74809 | Pliant Therapeutics | Closed |
| Nov 6, 2019 | A proof-of-concept and dose-ranging study investigating the efficacy and safety of HTD1801 in adult subjects with primary sclerosing cholangitis (PSC)HTD1801 (berberine ursodeoxycholate) | Hightide Biopharma Proprietary Limited | Closed |
| Jul 24, 2019 | A phase 2, randomized, double blind, placebo controlled, multiple center study to evaluate the safety, tolerability, and efficacy of seladelpar administered…Seladelpar | CymaBay Therapeutics | Ongoing |
| May 2, 2019 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of cilofexor in non-cirrhotic subjects with…Cilofexor (GS-9674) | Gilead Sciences | Closed |
| Sep 27, 2018 | A prospective, randomized, multi-centered, placebo-controlled, clinical trial of oral vancomycin in adults with primary sclerosing cholangitisVancomycin | Dr Johannes A (Bertus) Eksteen | Pending |
| Jul 21, 2026 | VolixibatTreatment of primary sclerosing cholangitis | Mirum Pharmaceuticals, Inc. | Designated |
| Jul 16, 2025 | ElafibranorTreatment of primary sclerosing cholangitis | IPSEN Bioscience Inc. | Designated |
| Apr 9, 2024 | Small molecule inhibitor of hyaluronan synthesisTreatment of primary sclerosing cholangitis | Halo Biosciences, Inc. | Designated |
| Dec 1, 2022 | Live biotherapeutic product consisting of a single…Treatment of Primary Sclerosing Cholangitis | LISCure Biosciences Inc. | Designated |
| Nov 15, 2022 | 3-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,…Treatment of Primary Sclerosing Cholangitis | Albireo AB | Designated |
| May 24, 2022 | Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-…Treatment of primary sclerosing cholangitis | Sterotherapeutics, LLC | Designated |
| Mar 28, 2022 | Beta-LapachoneTreatment of Primary Sclerosing Cholangitis (PSC) | Curome Biosciences Co., Ltd. | Designated |
| Sep 13, 2021 | 3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxa…Treatment of Primary Sclerosing Cholangitis | Cascade Pharmaceuticals, Inc | Designated |
| Jun 24, 2021 | Norucholic acidTreatment of Primary Sclerosing Cholangitis | Dr. Falk Pharma GmbH | Designated |
| Mar 4, 2020 | Glucagon-like peptide-1/Glucagon/Gastric inhibitory…Treatment of primary sclerosing cholangitis | Hanmi Pharmaceutical Company, Ltd. | Designated |
| Oct 25, 2018 | 2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-…Treatment of Primary Sclerosing Cholangitis (PSC) | Gilead Sciences, Inc. | Designated |
| Oct 11, 2018 | Monoclonal antibody targeting CCL24Treatment of primary sclerosing cholangitis | ChemomAb, Ltd. | Designated |
| Jul 6, 2017 | 5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)Treatment of primary sclerosing cholangitis (PSC) | DURECT Corporation | Designated |
| Jun 21, 2017 | (S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)p…Treatment of primary sclerosing cholangitis (PSC) | Conatus Pharmaceuticals | Designated |
| Jun 15, 2017 | CotsiranibTreatment of primary sclerosing cholangitis | Sirnaomics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA